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The antitumor, antibacterial and antioxidant activity, DNA interaction and cathepsin B inhibition of 43 
cyclo-orthopalladated and -platinated compounds [Pd(C,N)]2(μ-X)2 [X = OAc (1), X = Cl (2)] and 44 
trans-N,P-[M(C,N) X(PPh3)] [M = Pd, X = OAc (3), M = Pd, X = Cl (4), M = Pt, X = Cl (5)] are 45 
discussed [(C,N)= cyclo-orthometallated benzophenone imine]. The cytotoxicity of compound 5 has 46 
been evaluated towards human breast (MDA-MB-231 and MCF-7) and colon (HCT-116) cancer cell 47 
lines and that of compounds 1–4 towards the HCT-116 human colon cancer cell line. These 48 
cytotoxicities have been compared with those previously reported for compounds 1–4 towards MDA-49 
MB-231 and MCF-7 cancer cell lines. Compound 3 and 4 were approximately four timesmore active 50 
than cisplatin against theMDA-MB-231 andMCF-7 cancer cell lines, and compound 5, was 51 
approximately four times more potent than cisplatin against the HCT-116 cancer cell line. The 52 
antibacterial activity of compounds 1–5 was in between the ranges of activity of the commercial 53 
antibiotic compounds cefixime and roxithromycin. Complexes 1–2 and 4–5 presented also antioxidant 54 
activity. Compounds 1–5 alter the DNA tertiary structure in a similar way to cisplatin, but at higher 55 
concentration, and do not present a high efficiency as cathepsin B inhibitors. Compound 5 has not been 56 









The application of cyclometalated compounds in medicine and bioimaging is a subject of growing 64 
interest [1–3]. In this field, our research group has published some studies on the in vitro antitumor 65 
activity of cyclopalladated and cycloplatinated compounds [4–7]. The number of studies related to the 66 
anticancer activity of cyclopalladated and cycloplatinated compounds is quite significant [8,9] but very 67 
little is known about their other chemotherapeutic activities. Antiparasitic activity has been reported for 68 
a fewcyclopalladated and cycloplatinated compounds [5,10–12]. In addition, in a few cases the 69 
antibacterial activity of cyclopalladated compounds has also been studied [13–16]. Cycloaurated 70 
compounds have also been explored for their antibacterial, antifungal, antiviral and antiparasitic 71 
activities [12,17,18]. 72 
On the other hand, in recent years, it has become increasingly evident that several cytotoxic metallodrugs 73 
exert their biological and pharmacological actions through DNA-independent mechanisms. 74 
Accordingly, it is important to explore alternativemechanisms and biological targets for 75 
anticancermetallodrugs [19]. Cathepsin B is a cysteine metalloprotease highly upregulated in a wide 76 
variety of cancers by mechanisms ranging from gene amplification to post-transcriptional modification. 77 
The exact role of cathepsin B in solid tumors has yet to be defined, but it has been proposed to participate 78 
inmetastasis, angiogenesis, and tumor progression [20,21]. Recently, compounds based on palladium, 79 
platinum, ruthenium, rhenium, gold and tellurium were shown to be effective inhibitors of cathepsin B 80 
[12,20–31]. In addition, an excellent correlation between cathepsin B inhibition and cytotoxicity for 81 
some dinuclear biphosphane palladacycles [22] and mononuclear platinacycles containing a fluorinated 82 
phosphane [28] has been reported. Therefore within this work, we intended to study the capability of 83 
the cyclopalladated and cycloplatinated benzophenone imines 1–5 given in Scheme 1 to act as cytotoxic 84 
agents, by direct damage on DNA, or/and by inhibiting alternative targets such as cathepsin B, which is 85 
overexpressed in many cancer cell lines. 86 
In a precedent paper [32], we reported the antitumor activity of the cyclopalladated benzophenone 87 
imines 1–4 depicted in Scheme 1 against the MDA-MB-231 and MCF-7 human breast cancer cell lines 88 
and studied their interaction towards DNA by the DNA migration electrophoretic technique. Following 89 
this study, here we report: a) the antitumor activity of compounds 1–4 towards the HCT-116 human 90 
colon cancer cell line and that of the cycloplatinated compound 5 towards MDA-MB-231 and MCF-7 91 
breast and HCT-116 colon human cancer cell lines, b) the antibacterial activity of compounds 1–5, c) 92 
the antioxidant activity of compounds 1–5, expressed as their % of DPPH free radical scavenging, d) 93 
the interaction of compound 5 with DNA by the DNA migration agarose gel electrophoretic assay, and 94 








2.1. Chemistry: instruments and reagents 101 
 102 
Elemental analyses of C, H and N were performed with an Eager 1108 microanalyzer. Infrared spectra 103 
were recorded on a Nicolet Impact-400 spectrophotometer using pressed disks of dispersed samples of 104 
the compounds in KBr. 1H NMR (at 400 MHz), 13C–{1H} (at 101 MHz), 195Pt–{1H} (at 86 MHz), 105 
and 31P–{1H} (at 162 MHz) NMR spectra were recorded in CDCl3 at 298 K. Chemical shifts are 106 
reported in δ values (ppm) relative to SiMe4 (δ=0.00 ppm) for 1H NMR, to the residual solvent peak 107 
for 13C–{1H} (δ = 77.00 ppm), to a solution of K2[PtCl4] in D2O (δ = −1617.00 ppm) as an external 108 
reference for 195Pt–{1H} NMR, and relative to an external solution of trimethylphosphite in deuterated 109 
acetone (δ = 140.18 ppm relative to 85% orthophosphoric acid) for 31P–{1H} NMR. Coupling constants 110 
are given in Hz, and multiplicity (splitting) is expressed as s (singlet), d (doublet), m (multiplet), and br 111 
(broad signal). Low resolution ESI (+) mass spectrawere acquired on an LC/MSD-TOF instrument, 112 
utilizing a mixture of CH3CN:H2O (1:1, v/v) as the eluent. Dry methanol (HPLC grade), 113 
dichloromethane, hexanes, ethyl acetate, and diethyl ether were used as received. Sodium acetate was 114 
oven-dried at 60 ºC, prior to use. The complex cis-[PtCl2(DMSO)2] was prepared following a literature 115 
method [33]. Compounds 1–4 were prepared as previously reported [32]. ESI and LC/MSD-TOF refer 116 
to Electrospray Ionization and Liquid Chromatography/Mass Selective Detector — Time Of Flight, 117 
respectively. 118 
 119 
2.2. Preparation of mixture A 120 
 121 
Cis-[PtCl2(DMSO)2] (301 mg, 0.71 mmol) and sodium acetate (61 mg, 0.74 mmol) were brought into 122 
a Schlenk flask and evacuated for 10 min, and finally flushed with nitrogen. To this, dry methanol (50 123 
mL) was added and the reaction mixture was warmed until complete dissolution of the sample. An 124 
excess of benzophenone imine (150 μL, 162 mg, 0.89 mmol) was next added to the yellow solution, and 125 
the resultingmixture was refluxed for 1 day. After this time, dichloromethane (approx. 15 mL) was added 126 
to the red solution to induce precipitation of the sodium acetate. The suspension was filtered through a 127 
pad of celite (5.0 cm × 2.0 cm) and washed through with further dichloromethane until thewashingswent 128 
colorless. Evaporation of the solvent resulted in the formation of a resin, to which hexanes (ca. 15 mL) 129 
were added. The mixture was energetically stirred for 1–2 days, during which time intense scratching 130 
on the vessel surface was required to help promoting precipitation. The beige solid was collected by 131 
filtration and air-dried (305 mg). 1H NMR characterization in CDCl3 revealed that the major 132 
components of this solid are trans-N,L-[Pt(C,N)Cl(DMSO)] (A1) and trans-N,L-133 
[Pt(C,N)Cl(Ph2C=NH)] (A2) in a 3:1 molar ratio. 1H NMR (400MHz, CDCl3, 298 K) (selected data): 134 
A1: 8.83 (br s, 1 H, NH), 8.27 (d, 3JHH = 7.6, 3JPtH = 48.0, 1H, H2), 3.56 (s, 3JPtH = 21.4, 6H, CH3); 135 
A2: 10.0 (br s, 1H, NH), 8.92 (br s, 1H, NH), 8.29 (d, 3JHH = 7.2, partially overlapped with H2 of A1, 136 
1H, H2). MSESI (+) (CH3CN:H2O, (1:1)), m/z: A1: 494.1 (calcd. 494.1) [M − Cl + CH3CN]+, 453.1 137 







2.3. Preparation of compound 5 143 
 144 
The mixture A (297 mg) was dissolved in acetone (50 mL) giving an orange solution, which was 145 
subsequently treated with triphenylphosphane (160 mg, 0.61 mmol) at room temperature. After 2 h and 146 
30 min of stirring, the resulting mixture was concentrated under vacuum. Addition of diethyl ether 147 
(approx. 10 mL) produced the formation of a yellow precipitate, which was filtered and air-dried (290 148 
mg). An additional crop was obtained from the ether mother liquor, which was concentrated to dryness 149 
and afterwards vigorously stirred in hexanes (ca. 25 mL) for one day. The yellow solid formed was 150 
filtered off and dried in air (40 mg). Both crops were combined, dissolved in ethyl acetate, and subjected 151 
to column chromatography (SiO2, 3.0 cm × 30 cm) using a 100:60 hexanes:ethyl acetate mixture as 152 
eluent. The eluted band led to the required product after solvent removal and addition of hexanes (ca. 153 
10mL). The yellow solid obtained was recovered by filtration and air-dried (128 mg, 27% yield, relative 154 
to the starting cis-[PtCl2(DMSO)2]). Yellow crystals of 5 suitable for X-ray analysis were grown at 155 
room temperature from a dichloromethane solution layered by hexanes in a 1:1 volume ratio. IR 156 
(selected data), ν (cm−1): 3315 (NH st), 1583 (C = N st), 1096 (q, X-sensitive PPh3). 1H NMR (400 157 
MHz, CDCl3, 298 K): 9.34 (br s, 1 H, NH), 7.80–7.75 (m, 6 H, o-PPh3), 7.61–7.52 (m, 5 H, H8 + H9 158 
+ H10), 7.47–7.37 (m, 9 H, p-PPh3 + m-PPh3), 7.16 (d, 1 H, 3JHH = 7.8, H5), 6.92–6.88 (m, 1 H, H4), 159 
6.74–6.58 (m, 2 H, H2 + H3). 13C–{1H} NMR (101 MHz, CDCl3, 298 K): 189.1 (d, 3JCP = 2.6, C7 = 160 
NH), 145.9 (d, 3JCP = 1.5, C6), 145.3 (d, 2JCP = 6.7, C1), 137.8 (d, 3JCP = 5.9, C2), 135.4 (d, 2JCP = 161 
11.3, o-CPPh3), 134.9 (d, 4JCP = 5.0, C8), 132.7 (d, 4JCP = 2.0, C3), 131.3 (s, C5), 131.2 (s, C11), 162 
130.8 (d, 4JCP = 2.5, p-CPPh3), 130.1 (d, 1JCP = 60.2, i-CPPh3), 129.0 (s, C10), 128.0 (d, 3JCP = 11.0, 163 
m-CPPh3), 127.8 (s, C9), 122.6 (s, C4). 31P–{1H} NMR (162 MHz, CDCl3, 298 K): 22.64 (s, 1JPtP = 164 
4068). 195Pt–{1H} NMR (86 MHz, CDCl3, 298 K): −4206.6 (d, 1JPtP = 4109). MS-ESI (+) 165 
(CH3CN:H2O, (1:1)), m/z: 1309.2 (calcd. 1309.2) [2M − Cl]+, 678.2 (calcd. 678.2) [M − Cl + 166 
CH3CN]+, 637.1 (calcd. 637.1) [M−Cl]+. Anal. Calcd. for C31H25ClNPPt: C 55.32%, H 3.74%, N 167 
2.08%. Found: C 55.16%, H 3.81%, N 1.97%. 168 
 169 
2.4. X-ray crystal structure determination of compound 5 170 
 171 
A yellow prism-like specimen of compound 5 (C31H25ClNPPt), approximate dimensions 0.208 mm × 172 
0.249 mm × 0.554 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were 173 
measured on a D8 Venture system equipped with a multilayer monochromator and a Mo microfocus (λ 174 
= 0.71073 Å). A total of 2848 frames were collected. The total exposure time was 7.91 h. The frames 175 
were integrated with the Bruker SAINT software package [34] using a narrow-frame algorithm. The 176 
integration of the data using a triclinic unit cell yielded a total of 91349 reflections to a maximum θ 177 
angle of 36.42° (0.60 Å resolution), of which 24376 were independent (average redundancy 3.747, 178 
completeness = 99.7%, Rint = 4.35%) and 23182 (95.10%) were greater than 2σ(F2). The final cell 179 
constants of a = 9.709(1) Å, b = 10.255(1) Å, c = 14.027(2) Å, α = 74.231(3)°, β = 72.613(4)°, γ = 180 
77.491(4)°, volume = 1268.6(3) Å3, are based upon the refinement of the XYZ-centroids of 195 181 
reflections above 20 σ(I) with 5.583° b 2θ b 58.11°. Data were corrected for absorption effects using the 182 
multi-scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.727. 183 
The structure was solved and refined using the Bruker SHELXTL Software Package [35], with Z = 2 184 
for the formula unit, C31H25ClNPPt. The final anisotropic full-matrix least-squares refinement on F2 185 
with 316 variables converged at R1 = 1.67%, for the observed data and wR2 = 4.29% for all data. The 186 
goodness-of-fit was 1.116. The largest peak in the final difference electron density synthesis was 1.100 187 
e−/Å3 and the largest hole was −1.695 e−/Å3 with an RMS (Root Mean Square) deviation of 0.122 188 
e−/Å3. On the basis of the final model, the calculated density was 1.762 g/cm3 and F(000), 656 e − . 189 
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2.5. Cell culture 190 
 191 
Breast cancer [MCF-7 (Michigan Cancer Foundation-7) and MBAMD-231(M. D. Anderson-Metastasic 192 
Breast-231)] and colon cancer [HCT-116 (Human Colon Tumor-116)] cellswere grown as a monolayer 193 
culture in minimum essential medium (DMEM with L-glutamine, without glucose and without sodium 194 
pyruvate) in the presence of 10% heat-inactivated fetal calf serum, 10 mM D-glucose and 0.1% 195 
streptomycin/penicillin, in standard culture conditions (humidified air with 5% CO2 at 37 ºC). 196 
 197 
2.6. Cell viability assay 198 
 199 
A stock solution (50 mM) of each compound was prepared in high purity DMSO. Then, serial dilutions 200 
were made with DMSO (1:1) and finally a 1:500 dilution of the diluted solutions of compounds on cell 201 
media was prepared. In this way DMSO concentration in cell media was always the same. The assay 202 
was performed as described by Givens et al. [36]. HCT-116, MDA-MB-231 and MCF-7 cells were 203 
plated at 5000 cells/well, respectively, in 100 mL media in tissue culture 96-well plates (Cultek). After 204 
24 h, media was replaced by 100 mL/well of drug serial dilutions. Control wells did not contain 205 
compounds 1–5. Each point concentration was run in triplicate. Reagent blanks, containing media and 206 
colorimetric reagent without cells were run on each plate. Blank values were subtracted from test values 207 
and were routinely 5–10% of the control values. Plates were incubated 72 h. Hexosaminidase activity 208 
was measured according to the following protocol. The media were removed and cells were washed 209 
once with PBS (Phosphate Buffered Saline). Then, 60 mL of substrate solution (pnitrophenol-N-acetyl-210 
β-D-glucosamide 7.5 mM, sodium citrate 0.1 M at pH5.0, and 0.25% Triton X-100) was added to each 211 
well and incubated at 37 ºC for 1–2 h. After this incubation time, a bright yellow appeared. Then, the 212 
plates were developed by adding 90 mL of developer solution (glycine 50 mM, pH 10.4; EDTA 5 mM) 213 
and the absorbance was recorded at 410 nm. 214 
 215 
2.7. Antibacterial activity 216 
 217 
Test compounds (1–5) were screened to determine their antibacterial activity against six bacterial 218 
strains; three gram positive Staphylococcus aureus (ATCC 6538), Micrococcus luteus (ATCC 10240) 219 
and Bacillus subtilis (ATCC 6633) and three gram negative Escherichia coli (ATCC 15224), 220 
Enterobacter aerogenes (ATCC 13048) and Bordetella bronchiseptica (ATCC 4617) by using “Disc 221 
diffusion method” [37–39]. The organisms were cultured in nutrient broth at 37 °C for 24 h. One percent 222 
broth culture containing approx. 106 colony-forming units (CFU/mL) of test strain were added to 223 
nutrient agar medium at 45 °C and poured into sterile petri plates. The mediumwas allowed to solidify. 224 
Five microliters of the test compound (40 mg/mL in DMSO) was poured on 4-mm sterile paper disks 225 
and placed on nutrient agar plates respectively. In each plate DMSO served as negative control and 226 
standard antibacterial drugs roxithromycin (1 mg/mL) and cefixime (1 mg/mL) served as a positive 227 
control. Triplicate plates of each bacterial strainwere prepared. The plates were incubated at 37 °C for 228 






2.8. DPPH (1,1-diphenyl-2-picrylhydrazyl) free radical scavenging assay 233 
 234 
The scavenging activity of DPPH free radicals of compounds 1–5 was determined according to the 235 
method reported earlier with minor modifications [40,41]. A stock solution (5 mg/mL) of test solution 236 
was prepared in DMSO. Serial dilutions were carried out to obtain concentrations of 5, 10, 20, 40, 100, 237 
200 μg/mL. 15 μL of each test sample or DMSO in case of negative control was mixed with 2985 μL of 238 
0.1 mM methanolic solution of DPPH in glass vials so that the final volume was 3 mL. The vials were 239 
capped and reaction mixture was incubated for 30 min at 37 °C in dark. After incubation the change in 240 
colour (from deep-violet to light-yellow) of DPPH solution was measured by taking absorbance of 241 
reaction mixtures at 517 nm on a PDA (photo diode array) spectrophotometer (Agilent 8453). Mixture 242 
of 2985 μL of methanol and 15 μL of DMSOwas used as a blank for spectrophotometric measurements. 243 
Each concentration was assayed in triplicate. Ascorbic acid was used as a reference standard and 244 
dissolve in distilled water to make the stock solution with the same concentration (5 mg/mL). Control 245 
was prepared containing the same volume without any test solution and reference ascorbic acid. The % 246 
scavenging of the DPPH free radical was calculated by using the following formula. 247 
 248 
%scavenging activity  
absorbance of control-absorbance of test sample
absorbance of control
 x 100 249 
 250 
2.9. DNA migration studies 251 
 252 
A stock solution (10 mM) of each compound was prepared in high purity DMSO. Then, serial dilutions 253 
were made in MilliQ water (1:1). Plasmid pBluescript SK + (Stratagene) was obtained using QIAGEN 254 
plasmid midi kit as described by the manufacturer. Interaction of drugs with pBluescript SK + plasmid 255 
DNA was analyzed by agarose gel electrophoresis following a modification of the method described by 256 
Abdullah et al. [42]. Plasmid DNA aliquots (40 μg/mL)were incubated in TE buffer (10 mM Tris-HCl, 257 
1 mM EDTA, pH 7.5) with different concentrations of compounds 1–5 ranging from 0 μM to 200 μM 258 
at 37 ºC for 24 h. Final DMSO concentration in the reactions was always lower than 1%. For comparison, 259 
cisplatin and ethidium bromide were used as reference controls. Aliquots of 20 μL of the incubated 260 
solutions of compounds containing 0.8 μg of DNA were subjected to 1% agarose gel electrophoresis in 261 
TAE buffer (40 mM Tris-acetate, 2 mM EDTA, pH 8.0). The gelwas stained in TAE buffer containing 262 
ethidiumbromide (0.5 mg/mL) and visualized and photographed under UV light. 263 
 264 
2.10. Cathepsin B inhibition assay 265 
  266 
Aldrich (C6286). The colorimetric cathepsin B assay was performed as described by Casini et al. [27], 267 
with fewmodifications. Briefly, the reaction mixture contained 100 mM sodium phosphate (pH 6.0), 1 268 
mM EDTA and 200 μM sodium N-carbobenzoxy-L-lysine p-nitrophenyl ester as substrate. To have the 269 
enzyme catalytically active before each experiment the active site of the cysteine was reduced by 270 
treatment with dithiothreitol (DTT). For this purpose, 5 mM DTT was added to cathepsin B sample, 271 
before dilution, and incubated 1 h at 30 ºC. To test the inhibitory effect of the compounds 1–5 on 272 
cathepsin B, activity measurements were performed in triplicate using fixed concentrations of enzyme 273 
(500 nM) and substrate (200 μM). Compounds were used at concentrations ranging from 10 to 100 μM. 274 
Previous to the addition of substrate, cathepsin B was incubated with the different compounds at 25 ºC 275 
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for 24 h. The cysteine proteinase inhibitor E-64 was used as a positive control of cathepsin B inhibition. 276 
Complete inhibition was achieved at 10 μM concentration of E-64. Activity was measured over 1.5 min. 277 





3. Results and discussion 281 
 282 
3.1. Synthesis of compounds 1–5 283 
 284 
Scheme 1 shows the methods of preparation of compounds 1–5 and the numbering of the hydrogen and 285 
carbon atoms of the benzophenone imine for the discussion that follows. 286 
Cyclopalladated benzophenone imines 1–4 were prepared according to themethods recently reported by 287 
our research group [32]. Mixture A was prepared by a modification of the reported procedure for the 288 
cycloplatination of benzophenone imine [43,44]. Cis-[PtCl2(DMSO)2] and NaOAc inmolar ratio 1:1 289 
were treated with an excess of benzophenone imine in dry methanol under nitrogen and at reflux for 24 290 
h. In these conditions, we were able to isolate mixture A in a moderate amount, which contained as 291 
major components the cycloplatinated compounds [Pt(C,N)Cl(L)] A1 (L= DMSO) and A2 (L= 292 
benzophenone imine). Other minor compounds present in mixture A could not be characterized. Mixture 293 
A was studied by 1H NMR and ESI mass spectrometry. Analysis of the integrals of the 1H NMR 294 
indicates that compounds A1 and A2 were the major components of mixture A and that the molar ratio 295 
between them was A1/A2 ≈ 3/1. Compound 5 of formula trans-N,P-[Pt(C,N)Cl(PPh3)]was prepared by 296 
reaction between mixture A and PPh3 via a substitution reaction of the L ligand in compounds A1 and 297 
A2 for the PPh3 ligand. Compound 5 was obtained in 27% yield relative to the initial cis-298 
[PtCl2(DMSO)2] and was fully characterized by elemental analysis, IR, NMR and mass spectrometry. 299 
In addition, its crystal structure was determined by X-ray diffraction. 300 
In the IR spectrum, compound 5 presented the N\H and C_N stretchings and the q X sensitive band of 301 
the coordinated PPh3molecule at 3315, 1583 and 1096 cm−1, respectively [32]. In the ESI mass 302 
spectrometry, compound 5 produced intense signals for the cations [M − Cl + CH3CN]+ and [M − Cl]+, 303 
in accordance with the labile nature of Pt(II)\Cl σ bond and the coordinative nature of themolecules of 304 
acetonitrile, which was used as a solvent in this technique [45]. The most interesting features of the 1H 305 
NMR spectrum of compound 5 were: i) the lack of the signal due to theH1 proton,which demonstrated 306 
its ortho-metallated nature, ii) the chemical shift of its NH proton (9.34 ppm) relative to free 307 
benzophenone imine (8.40 ppm), which was consistent with the coordination of the iminic nitrogen to 308 
the platinum(II) center, and iii) the chemical shift of the H2–H5 protons of the ortho-platinated phenyl 309 
ring in the interval between 7.16 and 6.58 ppm, which was consistent with the trans-N,P configuration 310 
of compound 5 [32,45–48]. Protons H2–H5 present these low chemical shifts because they are located 311 
in the shielding zone of the PPh3 aromatic rings of compound 5 [32,35–38]. The kC1, kN chelate 312 
coordinationmode of the benzophenone imine in compound 5 could also be determined by 13C–{1H} 313 
NMR since, in this experiment, the 13C (C1 and C7) atoms produced doublets due to the coupling of 314 
these 13C nuclei with the 31P nucleus [45]. 315 
31P–{1H} NMR of compound 5 produced a singlet at 22.64 ppmwith the expected satellites for 195Pt 316 
with a coupling constant between 31P and 195Pt of 4068 Hz, and the 195Pt–{1H} NMR produced a 317 
doublet at −4206.6 ppm with a coupling constant between 31P and 195Pt of 4068 Hz. These chemical 318 
shifts for 31P and 195Pt and coupling constant between 31P and 195Pt were quite similar to those 319 
previously reported for compounds of formula trans-N,P-[Pt(C,N)Cl(PPh3)], being (C,N) an ortho-320 







3.2. Molecular crystal structure of compound 5 326 
 327 
Suitable crystals for the X-raymolecular crystal structure determination of compound 5 were grown by 328 
slow evaporation of a solution of compound 5 in CH2Cl2/hexane in a volume ratio 1:1. Compound 5 329 
crystallized in the triclinic space group P-1 with Z = 2. Fig. 1 shows the X-ray molecular structure of 5 330 
and gives selected distances and bond angles. The molecular structure determined by X-ray diffraction 331 
confirms the proposed structure for compound 5. The benzophenone imine is coordinated in a chelate 332 
form to the platinum(II) through the N1 and C13 atoms, and a chlorido ligand and the phosphorus atom 333 
of the triphenylphosphane ligand complete the square-planar coordination sphere of the platinum(II) 334 
center. The triphenylphosphane ligand is in trans position to the iminic nitrogen atom, in accordance 335 
with the trans-N,P configuration proposed for compound 5 by NMR. Distances and angles around the 336 
platinum(II) center are between the normal intervals [50], being the C(13)–Pt(1)–N(1) [79.80(5)°] and 337 
C(13)–Pt(1)–Cl(1) [167.74(4)°] those that deviated most fromthe ideal angles for a square planar-338 
geometry (90 and 180°). The atoms coordinated to the platinum(II) center (Cl1, P1, C13 and N1) were 339 
almost in a plane and the metalacycle (Pt1, C13, C8, C1 and N1) was practically planar. The N1 atom 340 
(−0.068 Å) for the coordination plane and the C1 (−0.045 Å) atom for the metalacycle were those that 341 
were deviated most from their respective planes. The coordination plane (Cl1, P1, C13 and N1) and the 342 
ortho-metalated phenyl ring (C13, C12, C11, C10, C9 and C8) were almost coplanar, being the angle 343 
between these two planes 4.84°, and the angle between the planes of the non-metalated phenyl ring (C7, 344 
C6, C5, C4, C3 and C2) and the metalacycle was 45.81°.  345 
 346 
3.3. Stability and behavior in solution of compounds 1–5 347 
 348 
Compounds 1–5 were stable for long periods of time in contact with air, both in the solid state and in 349 
CDCl3 solution. These compoundswere also soluble in DMSO. In this solvent, the dinuclear compounds 350 
1 and 2 should be converted by a splitting reaction into the mononuclear compounds I of formula trans-351 
N,S-[Pd(C,N)(S-DMSO)X] (X = OAc or Cl) [45,51]. In DMSO as solvent, the exchange of PPh3 for 352 
DMSO in compounds 3–5 does not seemlikely because the favorable thermodynamic reaction is the 353 
inverse of this reaction [52]. In addition, in the biological media, complexes I, 3, 4 and 5 could be 354 
converted into the ionic aqua complexes [Pd(C,N)(H2O)2]X (X= OAc, Cl) (compounds II) and trans- 355 
N,P-[M(C,N)(PPh3)(H2O)]X (M = Pd, X = OAc or Cl and M = Pt, X = Cl) (compounds III) by 356 
substitution of the chlorido and DMSO ligands of compounds I and the chlorido ligands of compounds 357 
3–5 for water molecules, respectively. Therefore, we propose that the species responsible for the 358 




3.4. Antiproliferative studies 363 
 364 
Compound 5was evaluated in vitro for inhibition of cell proliferation against MDA-MB-231 and MCF-365 
7 human breast cancer cell lines, using cisplatin as a positive control. All the investigated compounds 366 
(1–5) were also evaluated against the cisplatin resistant HCT-116 human colon cancer cell line using 367 
cisplatin as a reference. The effects of the assayed palladacycles (1–4) and platinacycle (5) on the growth 368 
of the selected cell lines were assessed after 72 h and the IC50 values of compounds 1–5 resulting from 369 
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an average of two experiments are listed in Table 1. The cytotoxicity of compounds 1–4 towards the 370 
human breast MDA-MB-231 andMCF-7 cancer cell lines has been previously reported and their IC50 371 
values are included in Table 1 for a comparative purpose [32]. 372 
The in vitro data for the antiproliferative effect of 1–5 (Table 1) reveals that the different complexes 373 
inhibit cell proliferation in varying degrees depending on the cell line assayed. Most of the compounds 374 
exhibited a remarkable antiproliferative activity with IC50 values lower than those of cisplatin in the 375 
three cell lines assayed. Platinacycle 5 showed the highest cytotoxicity towards the HCT-116 cancer 376 
cells, while palladacycles 3 and 4 were the most potent against the MDAMB-231 and MCF-7 cancer 377 
cells. Interestingly, platinacycle 5 was found to inhibit cell growth proliferation of the HCT-116 colon 378 
cell line at a concentration approximately four times lower than cisplatin. In addition, we reported 379 
recently [32] that compounds 3 and 4 were approximately four times more potent than cisplatin against 380 
the MDA-MB231 and MCF-7 human breast cancer cell lines. It should also be noted that free 381 
benzophenone iminewas not active against the studied tumor cell lines. 382 
 383 
3.5. Antibacterial activity 384 
 385 
Resistance to chemotherapeutic agents is a common drawback of both anticancer and anti-infectious 386 
treatments. Hence, there is a need for new class of chemotherapeutic drugs in treating cancer cells and 387 
pathogenic microorganisms.On the other hand, patientswith neoplastic disorderswho are subjected to 388 
chemotherapeutic treatment are susceptible to microbial infections due to the subsequent drop of 389 
immunity. Therefore, the search of single drugs,whichwould possess dual anticancer and antibacterial 390 
activity, might be advantageous both therapeutically and cost-effectively. 391 
Based on the previous assumptions, compounds 1–5 were screened for their antibacterial activity against 392 
three Gram-positive (S. aureus, M. luteus and B. subtilis) and three Gram-negative (E. coli, E. aerogenes 393 
and B. bronchi) bacterial strains by the disk diffusion method. The commercial antibiotics cefixime 394 
(third generation cephalosporin) and roxithromycin (semi-synthetic macrolide) were used as positive 395 
controls. The results of antibacterial activities in the form of MIC are summarized in Table 2. 396 
Compounds 1–5 showed varying degrees of antibacterial activity with MIC values in the interval 0.18–397 
0.34 μM against the studied Gram-positive and Gram-negative bacterial strains (see Table 2). The 398 
antibacterial activity of compounds 1–5 is in between the ranges of activity of the commercial antibiotic 399 
cefixime and roxithromycin. It is interesting to note that all of the compounds showed antibacterial 400 
activity against the Gram-negative E. aerogenes strain and that compounds 1–5 were more active against 401 
Gram-negative strains than Grampositive strains. This latter result is interesting since Gram-negative 402 
bacterial resistance is a burgeoning problem in intensive care units [53]. The best antibacterial activity 403 
was provided by platinacycle 5, which exhibit MIC values lower than that of roxithromycin against E. 404 
coli (Gram-negative), E. aerogenes (Gram-negative) and B. subtilis (Gram-positive). 405 
 406 
3.6. Antioxidant activity 407 
 408 
The potential preventive anticancer effects of antioxidants, found in high concentrations in many 409 
phytochemicals, have become a major focus of research in recent years. These agents block free radical 410 
formation as an important mediator of their anticancer effects. Despite accumulating evidence to suggest 411 
an important role of antioxidants in cancer prevention, there has been much controversy over their 412 
potential therapeutic applications [54–58]. Very recently, antioxidant phytochemicals have found a 413 
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chemopreventive effect in platins based chemotherapies [59–61]. Furthermore, the biological activity 414 
of specific platinum derivatives, such as the platinum nitrosyl complexes are presumable due in part to 415 
the antioxidant properties of the nitrosyl pharmacophore [62]. Therefore we were interested in 416 
evaluating the antioxidant capability of the studied cyclometalated complexes. 417 
The antioxidant activity of compounds 1–5 was evaluated by their DPPH (1,1-diphenyl-2-418 
picrylhydrazyl) free radical scavenging activity. The DPPH monoradical presents a strong absorption at 419 
517 nm, which gives place to its violet colour. DPPH colour changes to light yellow when it accepts an 420 
electron or a hydrogen atom from an antioxidant compound. This discoloration can be quantitatively 421 
measured from the change in absorbance. Free radical scavenging activity of antioxidant compounds is 422 
concentration-dependent. Then, the radical scavenging activity increases as concentration of the 423 
antioxidant compound increases, and a low IC50 value reflects a high antioxidant activity [40,41]. 424 
DPPH free radical scavenging activities of complexes 1–5 were assayed at six concentrations (200, 100, 425 
40, 20, 10 and 5 μg/mL) and the results are summarized in Table 3. Ascorbic acid was used as a positive 426 
control. As expected, DPPH free radical scavenging activity of tested compounds was concentration 427 
dependent. Hence higher radical scavenging was observed at higher concentrations, i.e. 200 μg/mL. 428 
DPPH scavenging analysis showed that compounds 1–2 and 4–5 are good scavengers of DPPH by 429 
scavenging 69–81% of the radicals at 200 μg/mL. This scavenging activity is very close to that of 430 
ascorbic acid (87%) at the same final concentration (200 μg/mL). IC50 values for complexes 1–2 and 431 
4–5 for the DPPH free radical scavenging were in the interval between 0.12 and 0.14 μM. It should be 432 
noted that the mononuclear palladium(II) compound 3, with the terminal acetate ligand did not present 433 
any significant antioxidant activity. At present, we cannot give a mechanism for the DPPH scavenging 434 




3.7. DNA migration studies 439 
 440 
The interaction of compound 5 withDNA was studied by its ability to modify the electrophoretic 441 
mobility of the supercoiled closed circular (ccc) and the open circular (oc) forms of pBluescript SK + 442 
plasmid DNA (Fig. 2). The ccc formusuallymoves faster due to its compact structure. For comparison 443 
purposes cisplatin and ethidium bromide were included in the experiment.When the test compounds 444 
were incubated with plasmid DNA at 37 ºC, they coordinated to DNA molecule,which in some 445 
extentwas cleaved into fragments, and the brightness of the band diminished in gel. 446 
In spite of the high antiproliferative activity of compound 5, it was less efficient than cisplatin for 447 
removing the supercoils frompBluescript SK+ plasmid DNA, suggesting that the unwinding of the DNA 448 
is not the key factor responsible of their cytotoxicity (Fig. 2) [32]. 449 
An unwinding experiment was performed with increasing concentration of compound 5 ranging from 0 450 
to 200 μM and 40 μg/mL of pBluescript (Fig. 2). In the presence of platinacycle 5, the rate of migration 451 
of the supercoiled band (ccc) decreased and tended to approach that of the nicked relaxed band (oc) at 452 
concentration 25 μM. At higher concentration, an unwinding of negative to positive supercoiled DNA 453 
was displayed in the electrophoretogram (Fig. 3, compound 5, lanes 6–8). The same effect was observed 454 
for cisplatin (Fig. 2, cisplatin, lanes 3 and 5). 455 
Compounds 1–4 were less efficient than compound 5 in removing the supercoils of DNA [32]. Up to 50 456 
μM, only a slight decrease in the rate of migration of the supercoiled closed circular form was observed 457 
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for the dinuclear compound 2. At 100 μM, palladium compounds 1–4 greatly altered the mobility of the 458 
plasmid DNA. The unwinding of negative to positive supercoiled DNA was also observed for the Pd(II) 459 
complexes 1–4 but at 200 μM. 460 
Thus, on the basis of the alteration of the electrophoretic mobility of pBluescript plasmid DNA, it is 461 
hypothesized that compounds 1–5 alter the DNA tertiary structure by the same mechanism than 462 
cisplatin, but at higher concentrations. 463 
 464 
3.8. Cathepsin B inhibition 465 
 466 
The cytotoxicity of some dinuclear biphosphane palladacycles (Fig. 3, compounds X) [22] and 467 
mononuclear platinacycles with a fluorinated phosphane ligand (Fig. 3, compounds Y) [28] has been 468 
related to their cathepsin B inhibitory properties. In addition, several mononuclear cyclopalladated and 469 
cycloaurated complexes (Fig. 3, compounds Z) with antiparasitic activity were also excellent inhibitors 470 
of cathepsin B [12]. Considering the interaction of cyclopalladated compounds with cathepsin B, it is 471 
worthy of mention that their inhibition properties are very dependent on their structure and their IC50 472 
values vary in a very wide range [22]. 473 
Based on the precedent results, we were interested in testing the efficiency of compounds 1–5 as 474 
inhibitors of cathepsin B. Fig. 4 shows that compounds 1–5 inhibit cathepsin B in a dose dependent 475 
manner but none of compounds 1–5 had a high efficiency as cathepsin B inhibitor. Among them, only 476 
compound 4 inhibited more than 50% the enzyme activity at 100 μM concentration. Platinacycle 5 477 
presented a cathepsin B inhibition efficiency lower than that of palladacycles 1–4. This result should be 478 
relatedwith the great reactivity of the palladium(II) centers in compounds 1–4 in relation to the 479 
platinum(II) center in compound 5 [8]. 480 
The low activity of compounds 1–5 for the inhibition of cathepsin B could be relatedwith an insufficient 481 
targeting of compounds 1–5 for the active site of cathepsin B orwith a lack of reactivity of their metal 482 
center for the active site of cathepsin B [63]. It should be noted that a hydrogen bond between the N–H 483 
function of compounds 1–5 and the anionic X ligand trans to the metalated carbon atom could render 484 






The chemotherapeutic properties of cyclopalladated and cycloplatinated benzophenone imines studied 489 
in this work and in a previous one [32] show that these kinds of compounds have potential as anticancer 490 
agents, and they also present antibacterial and antioxidant activity. The best results for the three activities 491 
reported here (cytotoxicity versus HC-T116 colon cancer cells, antibacterial activity 492 
againstGramnegative microorganisms and antioxidant properties) were found for the newly prepared 493 
and characterized cycloplatinated complex 5. 494 
Cyclopalladated compounds 3–4 showed a remarkable antiproliferative activity against MDA-MB-231 495 
and MCF-7 breast human cancer cell lines and produced an approximately four-fold increase in potency 496 
with regard to cisplatin [32]. In addition, platinacycle 5 also showed an approximately four-fold increase 497 
in potency in relation to cisplatin in human HCT-116 colon cancer cells [this work]. These results 498 
uncover a greater selectivity of platinacycle 5 against the HCT-116 colon cancer cell line, whereas 499 
palladacycles 3 and 4 exhibit a greater selectivity for MDA-MB231 and MCF-7 breast cancer cells. 500 
Interestingly, compounds 1–5 also presented antibacterial and antioxidant activity. Compounds 1–5 501 
exhibited greater activity against Gram-negative than against Gram-positive bacterial strains, with MIC 502 
values between those of the commercial antibiotic cefixime and roxithromycin. The platinumcompound 503 
5 turned out to bemore potent in antibacterial activity than palladiumcompounds 1–4. Complexes 1–2 504 
and 4–5 presented also antioxidant activity with IC50 values in the interval 0.12–0.14 μM. The nature 505 
of the metal center (Pt vs. Pd) does not discriminate upon the radical scavenging activity of the assayed 506 
cyclometalated complexes. 507 
With regard to plausible target biomolecules for compounds 1–5, these metalacycles altered the DNA 508 
tertiary structure in a similar way as the standard reference cisplatin but at higher concentrations. Thus, 509 
retardation of the DNA mobility was observed at 25 μM for compound 5 and at 100 μM for compounds 510 
1–4. On the other hand, compounds 1–5 did not present a high activity for the inhibition of cathepsin B, 511 
being palladacycles 1–4 more active than platinacycle 5 versus the inhibition of cathepsin B. Then, there 512 
is no correlation between the cytotoxic activity of the studied compounds 1–5 and their inhibitory 513 
activity on this cysteine protease. These results suggest that these classes of compounds (cyclopalladated 514 
and platinated benzophenone imines), both with good cytotoxic activity, operate via a different 515 
pharmacological mechanism in which DNA and cathepsin B are not the primary targets. 516 
Work is in progress in our research group with the aims of firstly finding out a plausible primary target 517 
biomolecule for these compounds, then to functionalize compounds 1–5 in an adequate form in order to 518 
increase their potency as anticancer agents, and also to study the mechanism through that these 519 
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Legends to figures  637 
 638 
Scheme 1. i) Pd(OAc)2 (stoichiometric), HOAc, 60 °C, 24 h; ii) LiCl (excess), acetone, r.t., 2 h; iii) 639 
PPh3 (stoichiometric), acetone, r.t., 2 h.; iv) cis-[PtCl2(DMSO)2], NaOAc (stoichiometric), 640 
benzophenone imine (excess), methanol, reflux, 24 h, under N2. 641 
 642 
Figure 1. Crystal structure of compound 5. Hydrogen atoms have been omitted for clarity. Selected 643 
bond distances (Å) and angles (°): Pt(1)–C(13) = 2.0110(12), Pt(1)–N(1) = 2.0485(10), Pt(1)–P(1) = 644 
2.2347(4), Pt(1)–Cl(1) = 2.3622(4), N(1)–C(1) = 1.3000(16), C(1)–C(8) = 1.4586(17), C(8)–C(13) = 645 
1.4279(17), C(13)–Pt(1)-N(1) = 79.80(5), C(13)–Pt(1)-P(1) = 96.66(4), N(1)–Pt(1)–P(1) = 173.76(3), 646 
C(13)–Pt(1)–Cl(1) = 167.74(4), N(1)–Pt(1)–Cl(1) = 88.09(3), P(1)–Pt(1)–Cl(1) = 95.584(14), C(8)–647 
C(13)–Pt(1) = 113.06(8), C(13)–C(8)–C(1) = 115.17(11), N(1)–C(1)–C(8) = 114.14(10). 648 
 649 
Figure 2. Interaction of pBluescript SK+ plasmidDNA (0.8 μg)with increasing concentrations of 650 
compound 5, cisplatin and ethidiumbromide. Lane 1: DNA only. Lane 2: 2.5 μM. Lane 3: 5 μM. Lane 651 
4: 10 μM. Lane 5: 25 μM. Lane 6: 50 μM. Lane 7: 100 μM. Lane 8: 200 μM. ccc=supercoiled closed 652 
circular DNA. oc = open circular DNA. 653 
 654 
Figure 3. Structural formula of the compounds under discussion for the cathepsin B inhibition. 655 
Compounds X: Dinuclear biphosphane palladacycles [reference 22]. Compounds Y: Mononuclear 656 
platinacycles with a fluorinated phosphane [reference 28]. Compounds Z: Mononuclear cyclopalladated 657 
and cycloautared compounds [reference 12]. 658 
 659 
Figure 4. Effect of compounds 1–5 on cathepsin B activity. The enzyme was preincubated for 24 h with 660 
10 μM (blue bars), 50 μM (brown bars) or 100 μM (green bars) of each compound. The activity is given 661 
as a percentage of the enzyme activity determined in the absence of the test compound. Data are shown 662 






Table 1 IC50 (μM) (50% inhibitory concentration) cytotoxicity for benzophenone imine, compounds 667 
1–5 and cisplatin. Data are shown as the mean values of two experiments performed in triplicate with 668 






Table 2 Antibacterial activity of compounds 1–5. S. aureus: Staphylococcus aureus. M. luteus: 673 
Micrococcus luteus. B. subtilis: Bacillus subtilis. E. coli: Escherichia coli. E. aerogenes: Enterobacter 674 







Table 3 Antioxidant activity of compounds 1–5 expressed as the % of DPPH free radical scavenging. 680 
Each concentration for the test compounds (200, 100, 40, 20, 10 and 5 μg/mL) was assayed in triplicate. 681 
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